Literature DB >> 35902727

Tumor-promoting properties of karyopherin β1 in melanoma by stabilizing Ras-GTPase-activating protein SH3 domain-binding protein 1.

Fan Yang1, Lin Li1, Zhenzhen Mu1, Pengyue Liu1, Ying Wang1, Yue Zhang1, Xiuping Han2.   

Abstract

The nuclear import receptor karyopherin β1 (KPNB1), a member of the Karyopherin protein family, is reported to be overexpressed in various cancers and promote carcinogenesis. By analyzing the correlation between the expression of KPNB1 and the overall survival rate of melanoma patients, we found that melanoma patients with higher expression of KPNB1 had worse survival. Furthermore, the database analyzed that the KPNB1 mRNA level was higher in melanoma samples than that in skin nevus tissues. We thus proposed that KPNB1 played a role in promoting melanoma development, and conducted gain-of- and loss-of-function experiments to test our hypothesis. We found that KPNB1 knockdown significantly retarded the growth and metastasis of melanoma cells in vitro and in vivo, and increased their sensitivity towards the anti-tumor drug cisplatin. KPNB1 overexpression had opposite effects. Notably, in melanoma cells, KPNB1 overexpression significantly decreased Ras-GTPase-activating protein SH3 domain-binding protein 1 (G3BP1) protein level, which was also overexpressed in melanoma samples and enhanced malignant behaviors of melanoma cells. We further demonstrated that KPNB1 overexpression induced deubiquitination of G3BP1, and prevented its degradation. However, KPNB1 overexpression hardly affected the nuclear translocation of G3BP1. Additionally, alterations induced by KPNB1 overexpression were partly reversed by G3BP1 inhibition. Therefore, the results suggest that KPNB1 may promote melanoma progression by stabilizing the G3BP1 protein. KPNB1-G3BP1 axis represents a potential therapeutic targetable node for melanoma.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35902727     DOI: 10.1038/s41417-022-00508-8

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  35 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Surgical management of melanoma brain metastases in patients treated with immunotherapy.

Authors:  Russell R Lonser; Debbie K Song; Jacob Klapper; Marygrace Hagan; Sungyoung Auh; P Benjamin Kerr; Deborah E Citrin; John D Heiss; Kevin Camphausen; Steven A Rosenberg
Journal:  J Neurosurg       Date:  2011-04-08       Impact factor: 5.115

Review 4.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

Review 5.  Malignant melanoma.

Authors:  J A Sanchez; W A Robinson
Journal:  Annu Rev Med       Date:  1993       Impact factor: 13.739

6.  A Small Organic Molecule Blocks EGFR Transport into the Nucleus by the Nonclassical Pathway Resulting in Repression of Cancer Invasion.

Authors:  Siyoung Ha; Jangho Jeong; Jiwon Oh; Sangmyung Rhee; Seung Wook Ham
Journal:  Chembiochem       Date:  2017-12-13       Impact factor: 3.164

7.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Authors:  Meghna Das Thakur; Fernando Salangsang; Allison S Landman; William R Sellers; Nancy K Pryer; Mitchell P Levesque; Reinhard Dummer; Martin McMahon; Darrin D Stuart
Journal:  Nature       Date:  2013-01-09       Impact factor: 49.962

8.  Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.

Authors:  Jian Yang; Yuqi Guo; Cuijie Lu; Ruohan Zhang; Yaoyu Wang; Liang Luo; Yanli Zhang; Catherine H Chu; Katherine J Wang; Sabrine Obbad; Wenbo Yan; Xin Li
Journal:  Oncogene       Date:  2019-02-11       Impact factor: 9.867

9.  Inhibition of KPNB1 Inhibits Proliferation and Promotes Apoptosis of Chronic Myeloid Leukemia Cells Through Regulation of E2F1.

Authors:  Teng Wang; Zhenglan Huang; Ningshu Huang; Yuhang Peng; Miao Gao; Xin Wang; Wenli Feng
Journal:  Onco Targets Ther       Date:  2019-12-02       Impact factor: 4.147

10.  KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.

Authors:  Wenwen Du; Jianjie Zhu; Yuanyuan Zeng; Ting Liu; Yang Zhang; Tingting Cai; Yulong Fu; Weijie Zhang; Ruochen Zhang; Zeyi Liu; Jian-An Huang
Journal:  Cell Death Differ       Date:  2020-11-02       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.